Real‐world use of second‐generation integrase strand transfer inhibitors ( <scp>INSTI</scp> ) as switch therapy in the prospective <scp>ANRS</scp> ‐ <scp>CO3</scp> ‐ <scp>AquiVIH</scp> ‐ <scp>NA</scp> cohort

In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.